From combinatorial chemistry to cancer-targeting peptides

Olulanu H. Aina, Ruiwu Liu, Julie Sutcliffe, Jan Marik, Chong-Xian Pan, Kit Lam

Research output: Contribution to journalArticle

205 Citations (Scopus)

Abstract

Several monoclonal antibodies that target cell surface receptors have gained approval by the U.S. Food and Drug Administration and are widely used in the treatment of some cancers. These include but are not limited to the anti-CD20 antibody Rituximab, used in lymphoma treatment, as well as anti-HER-2 antibody for breast cancer therapy. The efficacy of this cancer immunotherapy modality is, however, limited by the large size of the antibody (160 kd) and its relatively nonspecific binding to the reticuloendothelial system. This latter property is particularly problematic if the antibody is used as a vehicle to deliver radionuclides, cytotoxic drugs, or toxins to the tumor site. Peptides, peptidomimetic, or small molecules are thus attractive as alternative cell surface targeting agents for cancer imaging and therapy. Cancer cell surface targeting peptides can be derived from known native peptide hormones such as somatostatin and bombesin, or they can be identified through screening combinatorial peptide libraries against unknown cell surface receptor targets. Phage-display peptide library and one-bead one-compound (OBOC) combinatorial library methods have been successfully used to discover peptides that target cancer cells or tumor blood vessel endothelial cells. The phage-display peptide library method, because of its biological nature, can only display L-amino acid peptides. In contrast, the OBOC combinatorial library method allows for bead-surface display of peptides that contain L-amino acids, D-amino acids, unnatural amino acids, or other organic moieties. We have successfully used the OBOC method to discover and optimize ligands against unique cell surface receptors of prostate cancer, T- and B-cell lymphoma, as well as ovarian and lung cancers, and we have used some of these peptides to image xenografts in nude mice with high specificity. Here, we (i) review the literature on the use of phage-display and OBOC combinatorial library methods to discover cancer and tumor blood vessel targeting ligands, and (ii) report on the use of an ovarian cancer targeting ligand, OA02, as an in vivo PET imaging probe in a xenograft model in nude mice.

Original languageEnglish (US)
Pages (from-to)631-651
Number of pages21
JournalMolecular Pharmaceutics
Volume4
Issue number5
DOIs
StatePublished - Sep 2007

Fingerprint

Peptides
Peptide Library
Cell Surface Receptors
Neoplasms
Vascular Tissue Neoplasms
Amino Acids
Ligands
Heterografts
Nude Mice
Ovarian Neoplasms
Antibodies
Peptidomimetics
Bombesin
Mononuclear Phagocyte System
Peptide Hormones
T-Cell Lymphoma
B-Cell Lymphoma
United States Food and Drug Administration
Therapeutics
Somatostatin

Keywords

  • Cancer cell surface targeting agents
  • Combinatorial chemistry
  • Integrin
  • On-bead cell binding
  • One-bead one-compound library
  • Optical imaging
  • Peptide library
  • PET imaging
  • Phage-display

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

From combinatorial chemistry to cancer-targeting peptides. / Aina, Olulanu H.; Liu, Ruiwu; Sutcliffe, Julie; Marik, Jan; Pan, Chong-Xian; Lam, Kit.

In: Molecular Pharmaceutics, Vol. 4, No. 5, 09.2007, p. 631-651.

Research output: Contribution to journalArticle

Aina, Olulanu H. ; Liu, Ruiwu ; Sutcliffe, Julie ; Marik, Jan ; Pan, Chong-Xian ; Lam, Kit. / From combinatorial chemistry to cancer-targeting peptides. In: Molecular Pharmaceutics. 2007 ; Vol. 4, No. 5. pp. 631-651.
@article{38bf6016ee224f629e6c61af046eb1c5,
title = "From combinatorial chemistry to cancer-targeting peptides",
abstract = "Several monoclonal antibodies that target cell surface receptors have gained approval by the U.S. Food and Drug Administration and are widely used in the treatment of some cancers. These include but are not limited to the anti-CD20 antibody Rituximab, used in lymphoma treatment, as well as anti-HER-2 antibody for breast cancer therapy. The efficacy of this cancer immunotherapy modality is, however, limited by the large size of the antibody (160 kd) and its relatively nonspecific binding to the reticuloendothelial system. This latter property is particularly problematic if the antibody is used as a vehicle to deliver radionuclides, cytotoxic drugs, or toxins to the tumor site. Peptides, peptidomimetic, or small molecules are thus attractive as alternative cell surface targeting agents for cancer imaging and therapy. Cancer cell surface targeting peptides can be derived from known native peptide hormones such as somatostatin and bombesin, or they can be identified through screening combinatorial peptide libraries against unknown cell surface receptor targets. Phage-display peptide library and one-bead one-compound (OBOC) combinatorial library methods have been successfully used to discover peptides that target cancer cells or tumor blood vessel endothelial cells. The phage-display peptide library method, because of its biological nature, can only display L-amino acid peptides. In contrast, the OBOC combinatorial library method allows for bead-surface display of peptides that contain L-amino acids, D-amino acids, unnatural amino acids, or other organic moieties. We have successfully used the OBOC method to discover and optimize ligands against unique cell surface receptors of prostate cancer, T- and B-cell lymphoma, as well as ovarian and lung cancers, and we have used some of these peptides to image xenografts in nude mice with high specificity. Here, we (i) review the literature on the use of phage-display and OBOC combinatorial library methods to discover cancer and tumor blood vessel targeting ligands, and (ii) report on the use of an ovarian cancer targeting ligand, OA02, as an in vivo PET imaging probe in a xenograft model in nude mice.",
keywords = "Cancer cell surface targeting agents, Combinatorial chemistry, Integrin, On-bead cell binding, One-bead one-compound library, Optical imaging, Peptide library, PET imaging, Phage-display",
author = "Aina, {Olulanu H.} and Ruiwu Liu and Julie Sutcliffe and Jan Marik and Chong-Xian Pan and Kit Lam",
year = "2007",
month = "9",
doi = "10.1021/mp700073y",
language = "English (US)",
volume = "4",
pages = "631--651",
journal = "Foodborne Pathogens and Disease",
issn = "1535-3141",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - From combinatorial chemistry to cancer-targeting peptides

AU - Aina, Olulanu H.

AU - Liu, Ruiwu

AU - Sutcliffe, Julie

AU - Marik, Jan

AU - Pan, Chong-Xian

AU - Lam, Kit

PY - 2007/9

Y1 - 2007/9

N2 - Several monoclonal antibodies that target cell surface receptors have gained approval by the U.S. Food and Drug Administration and are widely used in the treatment of some cancers. These include but are not limited to the anti-CD20 antibody Rituximab, used in lymphoma treatment, as well as anti-HER-2 antibody for breast cancer therapy. The efficacy of this cancer immunotherapy modality is, however, limited by the large size of the antibody (160 kd) and its relatively nonspecific binding to the reticuloendothelial system. This latter property is particularly problematic if the antibody is used as a vehicle to deliver radionuclides, cytotoxic drugs, or toxins to the tumor site. Peptides, peptidomimetic, or small molecules are thus attractive as alternative cell surface targeting agents for cancer imaging and therapy. Cancer cell surface targeting peptides can be derived from known native peptide hormones such as somatostatin and bombesin, or they can be identified through screening combinatorial peptide libraries against unknown cell surface receptor targets. Phage-display peptide library and one-bead one-compound (OBOC) combinatorial library methods have been successfully used to discover peptides that target cancer cells or tumor blood vessel endothelial cells. The phage-display peptide library method, because of its biological nature, can only display L-amino acid peptides. In contrast, the OBOC combinatorial library method allows for bead-surface display of peptides that contain L-amino acids, D-amino acids, unnatural amino acids, or other organic moieties. We have successfully used the OBOC method to discover and optimize ligands against unique cell surface receptors of prostate cancer, T- and B-cell lymphoma, as well as ovarian and lung cancers, and we have used some of these peptides to image xenografts in nude mice with high specificity. Here, we (i) review the literature on the use of phage-display and OBOC combinatorial library methods to discover cancer and tumor blood vessel targeting ligands, and (ii) report on the use of an ovarian cancer targeting ligand, OA02, as an in vivo PET imaging probe in a xenograft model in nude mice.

AB - Several monoclonal antibodies that target cell surface receptors have gained approval by the U.S. Food and Drug Administration and are widely used in the treatment of some cancers. These include but are not limited to the anti-CD20 antibody Rituximab, used in lymphoma treatment, as well as anti-HER-2 antibody for breast cancer therapy. The efficacy of this cancer immunotherapy modality is, however, limited by the large size of the antibody (160 kd) and its relatively nonspecific binding to the reticuloendothelial system. This latter property is particularly problematic if the antibody is used as a vehicle to deliver radionuclides, cytotoxic drugs, or toxins to the tumor site. Peptides, peptidomimetic, or small molecules are thus attractive as alternative cell surface targeting agents for cancer imaging and therapy. Cancer cell surface targeting peptides can be derived from known native peptide hormones such as somatostatin and bombesin, or they can be identified through screening combinatorial peptide libraries against unknown cell surface receptor targets. Phage-display peptide library and one-bead one-compound (OBOC) combinatorial library methods have been successfully used to discover peptides that target cancer cells or tumor blood vessel endothelial cells. The phage-display peptide library method, because of its biological nature, can only display L-amino acid peptides. In contrast, the OBOC combinatorial library method allows for bead-surface display of peptides that contain L-amino acids, D-amino acids, unnatural amino acids, or other organic moieties. We have successfully used the OBOC method to discover and optimize ligands against unique cell surface receptors of prostate cancer, T- and B-cell lymphoma, as well as ovarian and lung cancers, and we have used some of these peptides to image xenografts in nude mice with high specificity. Here, we (i) review the literature on the use of phage-display and OBOC combinatorial library methods to discover cancer and tumor blood vessel targeting ligands, and (ii) report on the use of an ovarian cancer targeting ligand, OA02, as an in vivo PET imaging probe in a xenograft model in nude mice.

KW - Cancer cell surface targeting agents

KW - Combinatorial chemistry

KW - Integrin

KW - On-bead cell binding

KW - One-bead one-compound library

KW - Optical imaging

KW - Peptide library

KW - PET imaging

KW - Phage-display

UR - http://www.scopus.com/inward/record.url?scp=35548986989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35548986989&partnerID=8YFLogxK

U2 - 10.1021/mp700073y

DO - 10.1021/mp700073y

M3 - Article

C2 - 17880166

AN - SCOPUS:35548986989

VL - 4

SP - 631

EP - 651

JO - Foodborne Pathogens and Disease

JF - Foodborne Pathogens and Disease

SN - 1535-3141

IS - 5

ER -